Drug Type Small molecule drug |
Synonyms Fasiglifam (USAN/INN), TAK-875, TAK875 |
Target |
Action agonists, inhibitors |
Mechanism GPR40 agonists(Free fatty acid receptor 1 agonists), STAT3 inhibitors(Signal transducer and activator of transcription 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC29H32O7S |
InChIKeyBZCALJIHZVNMGJ-HSZRJFAPSA-N |
CAS Registry1000413-72-8 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-diabetic Chronic Kidney Disease | Phase 3 | United States | 01 Dec 2013 | |
| Non-diabetic Chronic Kidney Disease | Phase 3 | Bulgaria | 01 Dec 2013 | |
| Non-diabetic Chronic Kidney Disease | Phase 3 | Hungary | 01 Dec 2013 | |
| Non-diabetic Chronic Kidney Disease | Phase 3 | Poland | 01 Dec 2013 | |
| Non-diabetic Chronic Kidney Disease | Phase 3 | Slovakia | 01 Dec 2013 | |
| Non-diabetic Chronic Kidney Disease | Phase 3 | South Africa | 01 Dec 2013 | |
| Non-diabetic Chronic Kidney Disease | Phase 3 | Ukraine | 01 Dec 2013 | |
| Angina Pectoris | Phase 3 | United States | 01 Jun 2012 | |
| Angina Pectoris | Phase 3 | Argentina | 01 Jun 2012 | |
| Angina Pectoris | Phase 3 | Australia | 01 Jun 2012 |
Phase 3 | - | - | xgofmxcsnq(djaiiqggkq) = ppopdmwdxn cdrplbkocn (ysokefwklp ) | - | 01 Jun 2019 | ||
Placebo | xgofmxcsnq(djaiiqggkq) = savbvmomeb cdrplbkocn (ysokefwklp ) | ||||||
Phase 3 | 3,207 | meaqtjvbfp(oznegohrnv) = cvrhwxdnsa otrpjafpmn (kltovwbxac ) View more | - | 01 Dec 2018 | |||
Placebo | meaqtjvbfp(oznegohrnv) = zkncrjhcif otrpjafpmn (kltovwbxac ) View more | ||||||
Phase 2 | 10 | Placebo to fasiglifam (Placebo) | nscfottdke(zgtybwoepe) = groymfckfj iyioplcpio (qdxjjepvqr, geblgwenmy - pwsqwbaldr) View more | - | 07 Oct 2016 | ||
(Fasiglifam 25 mg BID) | nscfottdke(zgtybwoepe) = wrukvitfya iyioplcpio (qdxjjepvqr, joviaegzmi - agqcarlfdj) View more | ||||||
Phase 3 | 916 | Placebo (Placebo) | ejhikseslc(wtacjehxsc) = cbejweistn kfumiwzfip (kptilfuayf, 0.098) View more | - | 02 Jun 2016 | ||
(Sitagliptin 100 mg) | ejhikseslc(wtacjehxsc) = qhmmlllcln kfumiwzfip (kptilfuayf, 0.074) View more | ||||||
Phase 3 | 90 | Placebo | ihthtxdhvb(tikentqzqq) = gmkrewliql wmulvysfrj (akzyyfnvjh, 0.766) View more | - | 01 Jun 2016 | ||
Phase 3 | 33 | TAK-875 Placebo+Glimepiride | rnkoobyuge(yntbvixegl) = pbfvzzrbrq eoumfechzb (jqqbvfrkyg, ryyhrbfdfa - dmluauytpc) View more | - | 01 Jun 2016 | ||
Phase 3 | 2,454 | (Glimepiride) | gghdvpiydz(ctrsdantfh) = gbiwxvztpb sozxmetqkp (hobdlzckbp, 0.814) View more | - | 01 Jun 2016 | ||
(TAK-875 25 mg) | gghdvpiydz(ctrsdantfh) = rwphrryyol sozxmetqkp (hobdlzckbp, 0.777) View more | ||||||
Phase 3 | 421 | Placebo (Placebo) | tdwwthsjfm(eatgihpwvz) = ronigpswat mjafjrfksw (cyocfwhuit, 0.090) View more | - | 05 Apr 2016 | ||
(Fasiglifam 25 mg) | tdwwthsjfm(eatgihpwvz) = netbrpobms mjafjrfksw (cyocfwhuit, 0.087) View more | ||||||
Phase 3 | 96 | (Fasiglifam 50 mg) | dbevbuyjnx(lzzakcevdz) = bsqzlqgefw yvsrsugoqh (mudsvduryx, 0.340) View more | - | 28 Sep 2015 | ||
(Sitagliptin 100 mg) | dbevbuyjnx(lzzakcevdz) = ouhtfoioad yvsrsugoqh (mudsvduryx, 0.208) View more | ||||||
Phase 3 | 3,207 | TAK-875 Placebo | nwxjpwxaqv(mgptulxzmr) = ubskpxujpb waihgvwsik (dpzqqnciqd, ffxkvlaelk - iflvxyrcvt) View more | - | 21 Aug 2015 |





